Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

MedSIR: Clinical Trials & FDA Approval Profile

MedSIR (Global / Institutional) sponsors 40 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (6 recruiting now), 15 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)22.5%
Median Closed Enrollment vs National (145 pts)47 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for MedSIR
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)40
Active Pipeline (Recruiting Now)16 (6)
Completed vs Stopped Early15 / 9 (22.5%)
Median Closed Actual Enrollment47 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With MedSIR
Hospital Research SiteLocationShared Protocols
Hospital Universitario Virgen del RocíoSeville12
Hospital Universitario Ramón y CajalMadrid10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by MedSIR
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07195227Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerPhase IIRECRUITING
NCT06180356Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionPhase IIRECRUITING
NCT06315010Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisPhase IIRECRUITING
NCT06382948Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Phase IIIRECRUITING
NCT05708235A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the MedSIR Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI